The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics
E Karran, B De Strooper - Nature Reviews Drug Discovery, 2022 - nature.com
Many drugs that target amyloid-β (Aβ) in Alzheimer disease (AD) have failed to demonstrate
clinical efficacy. However, four anti-Aβ antibodies have been shown to mediate the removal …
clinical efficacy. However, four anti-Aβ antibodies have been shown to mediate the removal …
The probabilistic model of Alzheimer disease: the amyloid hypothesis revised
The current conceptualization of Alzheimer disease (AD) is driven by the amyloid
hypothesis, in which a deterministic chain of events leads from amyloid deposition and then …
hypothesis, in which a deterministic chain of events leads from amyloid deposition and then …
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
CR Jack Jr, JS Andrews, TG Beach… - Alzheimer's & …, 2024 - Wiley Online Library
Abstract The National Institute on Aging and the Alzheimer's Association convened three
separate work groups in 2011 and single work groups in 2012 and 2018 to create …
separate work groups in 2011 and single work groups in 2012 and 2018 to create …
[HTML][HTML] Integrated multimodal cell atlas of Alzheimer's disease
Alzheimer's disease (AD) is the leading cause of dementia in older adults. Although AD
progression is characterized by stereotyped accumulation of proteinopathies, the affected …
progression is characterized by stereotyped accumulation of proteinopathies, the affected …
Biomarkers for neurodegenerative diseases
O Hansson - Nature medicine, 2021 - nature.com
Biomarkers for neurodegenerative diseases are needed to improve the diagnostic workup in
the clinic but also to facilitate the development and monitoring of effective disease-modifying …
the clinic but also to facilitate the development and monitoring of effective disease-modifying …
Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group
Summary In 2018, the US National Institute on Aging and the Alzheimer's Association
proposed a purely biological definition of Alzheimer's disease that relies on biomarkers …
proposed a purely biological definition of Alzheimer's disease that relies on biomarkers …
Synergy between amyloid-β and tau in Alzheimer's disease
Patients with Alzheimer's disease (AD) present with both extracellular amyloid-β (Aβ)
plaques and intracellular tau-containing neurofibrillary tangles in the brain. For many years …
plaques and intracellular tau-containing neurofibrillary tangles in the brain. For many years …
[HTML][HTML] Past, present and future of therapeutic strategies against amyloid-β peptides in Alzheimer's disease: A systematic review
Alzheimer's disease (AD) is the most prevalent neurodegenerative disease in ageing,
affecting around 46 million people worldwide but few treatments are currently available. The …
affecting around 46 million people worldwide but few treatments are currently available. The …
Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer's disease
Alzheimer's disease (AD) is the most common neurodegenerative disorder seen in age-
dependent dementia. There is currently no effective treatment for AD, which may be …
dependent dementia. There is currently no effective treatment for AD, which may be …
Pyroptosis in Alzheimer's disease: cell type-specific activation in microglia, astrocytes and neurons
S Moonen, MJ Koper, E Van Schoor… - Acta …, 2023 - Springer
The major neuropathological hallmarks of Alzheimer's disease (AD) are amyloid β (Aβ)
plaques and neurofibrillary tangles (NFT), accompanied by neuroinflammation and neuronal …
plaques and neurofibrillary tangles (NFT), accompanied by neuroinflammation and neuronal …